RecruitingNCT06504225
EVEROLD LONG TERM FOLLOW-UP
Long-term Evaluation of the Value of Using an MTor Inhibitor (everolimus) for the Minimisation of Anticalceurins in Old-for-old Kidney Transplantation
Sponsor
University Hospital, Brest
Enrollment
260 participants
Start Date
Aug 23, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
Long Term Follow up of EVEROLD study
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Informed patients participating to the EVEROLD study
- Patient having completed the EVEROLD M12 follow-up visit
- Patient agreeing to participate in the observational study
Exclusion Criteria2
- Opposition to the use his medical data
- Patient under legal protection
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(14)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06504225